Which has better valuation and earnings, ARGX or AMGN?

Amgen has higher revenue and earnings than argenex. Amgen is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.54 $1.29B $26.04 32.69 Amgen $36.75B 6.11 $7.71B $16.09 25.81

Is ARGX or AMGN more profitable?

argenex has a net margin of 32.19% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Amgen 22.95% 124.14% 13.18%

Does the media favor ARGX or AMGN?

In the previous week, Amgen had 21 more articles in the media than argenex. MarketBeat recorded 32 mentions for Amgen and 11 mentions for argenex. Amgen's average media sentiment score of 0.99 beat argenex's score of 0.87 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 23 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GILD or ARGX?

Gilead Sciences has higher revenue and earnings than argenex. Gilead Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 5.83 $8.51B -$2.67 N/A argenex $4.25B 12.54 $1.29B $26.04 32.69

Is GILD or ARGX more profitable?

argenex has a net margin of 32.19% compared to Gilead Sciences' net margin of -10.64%. argenex's return on equity of 43.59% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% argenex 32.19% 43.59% 36.66%

Does the media prefer GILD or ARGX?

In the previous week, Gilead Sciences had 27 more articles in the media than argenex. MarketBeat recorded 38 mentions for Gilead Sciences and 11 mentions for argenex. Gilead Sciences' average media sentiment score of 0.91 beat argenex's score of 0.87 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 21 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARGX or VRTX?

In the previous week, Vertex Pharmaceuticals had 13 more articles in the media than argenex. MarketBeat recorded 24 mentions for Vertex Pharmaceuticals and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Vertex Pharmaceuticals' score of 0.32 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to REGN or ARGX?

In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than argenex. MarketBeat recorded 36 mentions for Regeneron Pharmaceuticals and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Regeneron Pharmaceuticals' score of 0.55 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or ARGX?

In the previous week, Revolution Medicines had 1 more articles in the media than argenex. MarketBeat recorded 12 mentions for Revolution Medicines and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Revolution Medicines' score of 0.84 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

argenex (ARGX) Competitors

$851.29 -5.65 (-0.66%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$850.95 -0.34 (-0.04%)

As of 08/14/2026 07:34 PM Eastern

Compare

ARGX vs. AMGN, GILD, VRTX, REGN, and RVMD

Should you buy argenex stock or one of its competitors? argenex's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does argenex compare to Amgen?

argenex (NASDAQ:ARGX) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

60.3% of argenex shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amgen has higher revenue and earnings than argenex. Amgen is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.54	$1.29B	$26.04	32.69
Amgen	$36.75B	6.11	$7.71B	$16.09	25.81

argenex has a net margin of 32.19% compared to Amgen's net margin of 22.95%. Amgen's return on equity of 124.14% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Amgen	22.95%	124.14%	13.18%

argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

argenex currently has a consensus target price of $1,056.89, indicating a potential upside of 24.15%. Amgen has a consensus target price of $372.39, indicating a potential downside of 10.31%. Given argenex's stronger consensus rating and higher probable upside, research analysts plainly believe argenex is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Amgen	3 Sell rating(s)	15 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Amgen had 21 more articles in the media than argenex. MarketBeat recorded 32 mentions for Amgen and 11 mentions for argenex. Amgen's average media sentiment score of 0.99 beat argenex's score of 0.87 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	23 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Amgen on 11 of the 17 factors compared between the two stocks.

How does argenex compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gilead Sciences presently has a consensus target price of $158.04, suggesting a potential upside of 14.22%. argenex has a consensus target price of $1,056.89, suggesting a potential upside of 24.15%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Gilead Sciences has higher revenue and earnings than argenex. Gilead Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.83	$8.51B	-$2.67	N/A
argenex	$4.25B	12.54	$1.29B	$26.04	32.69

Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Gilead Sciences' net margin of -10.64%. argenex's return on equity of 43.59% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
argenex	32.19%	43.59%	36.66%

In the previous week, Gilead Sciences had 27 more articles in the media than argenex. MarketBeat recorded 38 mentions for Gilead Sciences and 11 mentions for argenex. Gilead Sciences' average media sentiment score of 0.91 beat argenex's score of 0.87 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	21 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Gilead Sciences on 11 of the 17 factors compared between the two stocks.

How does argenex compare to Vertex Pharmaceuticals?

argenex (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Vertex Pharmaceuticals has a net margin of 35.00% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

60.3% of argenex shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

argenex currently has a consensus price target of $1,056.89, suggesting a potential upside of 24.15%. Vertex Pharmaceuticals has a consensus price target of $563.50, suggesting a potential upside of 11.42%. Given argenex's higher possible upside, research analysts plainly believe argenex is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

Vertex Pharmaceuticals has higher revenue and earnings than argenex. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.54	$1.29B	$26.04	32.69
Vertex Pharmaceuticals	$12.59B	10.20	$3.95B	$17.18	29.44

In the previous week, Vertex Pharmaceuticals had 13 more articles in the media than argenex. MarketBeat recorded 24 mentions for Vertex Pharmaceuticals and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Vertex Pharmaceuticals' score of 0.32 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

argenex beats Vertex Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does argenex compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than argenex. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.77	$4.50B	$40.46	19.86
argenex	$4.25B	12.54	$1.29B	$26.04	32.69

In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than argenex. MarketBeat recorded 36 mentions for Regeneron Pharmaceuticals and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Regeneron Pharmaceuticals' score of 0.55 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	14 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Regeneron Pharmaceuticals' net margin of 27.86%. argenex's return on equity of 43.59% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
argenex	32.19%	43.59%	36.66%

Regeneron Pharmaceuticals currently has a consensus price target of $793.74, suggesting a potential downside of 1.21%. argenex has a consensus price target of $1,056.89, suggesting a potential upside of 24.15%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Regeneron Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does argenex compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
argenex	$4.25B	12.54	$1.29B	$26.04	32.69

Revolution Medicines presently has a consensus target price of $161.79, suggesting a potential downside of 20.58%. argenex has a consensus target price of $1,056.89, suggesting a potential upside of 24.15%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Revolution Medicines had 1 more articles in the media than argenex. MarketBeat recorded 12 mentions for Revolution Medicines and 11 mentions for argenex. argenex's average media sentiment score of 0.87 beat Revolution Medicines' score of 0.84 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 43.59% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
argenex	32.19%	43.59%	36.66%

Summary

argenex beats Revolution Medicines on 11 of the 16 factors compared between the two stocks.

Get argenex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARGX vs. The Competition

Export

Metric	argenex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.61B	$3.72B	$7.02B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	32.69	10.72	271.00	25.33
Price / Sales	12.54	1,241.21	583.09	76.83
Price / Cash	40.17	102.88	70.48	50.90
Price / Book	6.33	16.78	12.92	6.25
Net Income	$1.29B	-$13.32M	$3.45B	$347.82M
7 Day Performance	-1.59%	1.75%	1.15%	1.08%
1 Month Performance	-1.35%	1.13%	1.37%	0.82%
1 Year Performance	30.20%	54.35%	62.52%	20.99%

argenex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARGX argenex	4.8115 of 5 stars	$851.29 -0.7%	$1,056.89 +24.2%	+30.5%	$53.61B	$4.25B	32.69	1,863	Analyst Downgrade
AMGN Amgen	3.8391 of 5 stars	$378.87 -1.6%	$357.00 -5.8%	+43.0%	$207.87B	$36.75B	26.37	31,500	Analyst Forecast Insider Trade
GILD Gilead Sciences	4.4335 of 5 stars	$131.15 +0.7%	$157.93 +20.4%	+16.2%	$161.66B	$29.44B	17.87	17,000	Trending News Analyst Downgrade Options Volume Analyst Revision
VRTX Vertex Pharmaceuticals	4.4188 of 5 stars	$470.72 -1.3%	$559.61 +18.9%	+29.6%	$121.09B	$12.00B	27.92	6,400
REGN Regeneron Pharmaceuticals	3.7982 of 5 stars	$759.24 -0.4%	$797.75 +5.1%	+42.0%	$80.63B	$14.34B	18.77	15,410	Trending News Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARGX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Competitors

ARGX vs. AMGN, GILD, VRTX, REGN, and RVMD

How does argenex compare to Amgen?

Summary

How does argenex compare to Gilead Sciences?

Summary

How does argenex compare to Vertex Pharmaceuticals?

Summary

How does argenex compare to Regeneron Pharmaceuticals?

Summary

How does argenex compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Competitors

ARGX vs. AMGN, GILD, VRTX, REGN, and RVMD

How does argenex compare to Amgen?

Do insiders and institutionals hold more shares of ARGX or AMGN?

Which has better valuation and earnings, ARGX or AMGN?

Is ARGX or AMGN more profitable?

Which has more volatility & risk, ARGX or AMGN?

Do analysts prefer ARGX or AMGN?

Does the media favor ARGX or AMGN?

Summary

How does argenex compare to Gilead Sciences?

Do insiders & institutionals hold more shares of GILD or ARGX?

Do analysts prefer GILD or ARGX?

Which has stronger valuation and earnings, GILD or ARGX?

Which has more volatility and risk, GILD or ARGX?

Is GILD or ARGX more profitable?

Does the media prefer GILD or ARGX?

Summary

How does argenex compare to Vertex Pharmaceuticals?

Is ARGX or VRTX more profitable?

Do institutionals and insiders hold more shares of ARGX or VRTX?

Which has more risk & volatility, ARGX or VRTX?

Do analysts prefer ARGX or VRTX?

Which has better valuation & earnings, ARGX or VRTX?

Does the media prefer ARGX or VRTX?

Summary

How does argenex compare to Regeneron Pharmaceuticals?

Do insiders & institutionals hold more shares of REGN or ARGX?

Which has higher valuation and earnings, REGN or ARGX?

Does the media refer more to REGN or ARGX?

Which has more volatility and risk, REGN or ARGX?

Is REGN or ARGX more profitable?

Do analysts rate REGN or ARGX?

Summary

How does argenex compare to Revolution Medicines?

Which has preferable earnings & valuation, RVMD or ARGX?

Do analysts rate RVMD or ARGX?

Does the media prefer RVMD or ARGX?

Which has more risk & volatility, RVMD or ARGX?

Do insiders and institutionals hold more shares of RVMD or ARGX?

Is RVMD or ARGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools